文献速递神经免疫

CHIMES试验:奥瑞珠单抗治疗黑人与西班牙裔多发性硬化两年结果

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.
PubMed 文献 · Ann Neurol · 2026-07-30

CHIMES是一项前瞻性、开放标签、单臂4期试验,纳入美国、波多黎各和肯尼亚的黑人与西班牙裔复发型多发性硬化患者,接受奥瑞珠单抗治疗2年。第48周50.5%患者达到三组分无疾病活动证据,严重不良事件发生率8.2%,2.2%停药。

要点

  • 第48周50.5%患者达到无疾病活动证据,94.5%无24周确认残疾进展。
  • 严重不良事件发生率8.2%,仅2.2%因不良反应停药。
  • 西班牙裔输液相关反应更常见,黑人胃肠道不良事件更常见。

核心结论

  • 奥瑞珠单抗能控制黑人与西班牙裔复发型多发性硬化患者的疾病活动,结果与关键性试验一致,支持其在这两类人群中的有效性和耐受性。

研究设计与样本

  • CHIMES为前瞻性、开放标签、单臂4期研究,在美国、波多黎各和肯尼亚有意招募代表性不足人群。
  • 纳入18-65岁、扩展残疾状态量表评分0-5.5的黑人与西班牙裔复发型多发性硬化患者,接受奥瑞珠单抗治疗2年。
  • 共纳入113名黑人和69名西班牙裔患者,多数为女性(72%),平均年龄35.5岁(SD 10.5),平均体重指数31.0 kg/m2(SD 7.4),平均扩展残疾状态量表评分2.4(SD 1.4)。

主要发现

  • 第48周50.5%的CHIMES参与者达到三组分无疾病活动证据。
  • 第48周94.5%无24周确认残疾进展,95.1%无复发,95.6%无T1增强病灶,52.7%无新发/扩大T2病灶。
  • 严重不良事件发生于8.2%的患者,2.2%停止治疗。
  • 西班牙裔相比黑人输液相关反应更频繁(42.0% vs 29.2%),黑人相比西班牙裔胃肠道不良事件更频繁(23.0% vs 1.4%)。

关键数值与推荐

  • 主要终点为第48周三组分无疾病活动证据的比例,三组分为方案定义复发、24周确认残疾进展和磁共振成像疾病活动。
  • 第48周无疾病活动证据比例为50.5%,无24周确认残疾进展比例为94.5%,无复发比例为95.1%,无T1增强病灶比例为95.6%,无新发/扩大T2病灶比例为52.7%。
  • 严重不良事件发生率8.2%,停药率2.2%,西班牙裔输液相关反应42.0% vs 黑人29.2%,黑人胃肠道不良事件23.0% vs 西班牙裔1.4%。

临床怎么用

  • 对于黑人与西班牙裔复发型多发性硬化患者,奥瑞珠单抗可作为控制疾病活动的治疗选择。
  • 用药期间需关注西班牙裔患者的输液相关反应和黑人患者的胃肠道不良事件。

局限性

  • 本研究为单臂、开放标签设计,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of ocrelizumab in self-identified black and Hispanic people with relapsing multiple sclerosis. METHODS: The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open-label, single-arm, phase 4 study, intentionally recruited underrepresented populations in the US, Puerto Rico, and Kenya. Black and Hispanic people with relapsing multiple sclerosis aged 18-65 years with Expanded Disability Status Scale score 0-5.5 received ocrelizumab for 2 years. The primary endpoint was the proportion of participants with no evidence of disease activity in 3 components at week 48: protocol-defined relapse, 24-week confirmed disability progression, and disease activity on magnetic resonance imaging. RESULTS: Of 113 black and 69 Hispanic people with relapsing multiple sclerosis, most were women (72%), with a mean age of 35.5 (SD 10.5) years, body mass index of 31.0 (SD 7.4) kg/m2, and Expanded Disability Status Scale score of 2.4 (SD 1.4). Genetic ancestry aligned with self-identified race or ethnicity. At week 48, 50.5% of CHIMES participants had no evidence of disease activity, including 94.5% free from 24-week confirmed disability progression, 95.1% free from relapse, 95.6% free from T1-contrast-enhancing lesions, and 52.7% free from new/enlarging T2 lesions. Serious adverse events were experienced by 8.2%, and 2.2% discontinued treatment. Infusion-related reactions were more frequent in Hispanic versus black participants (42.0% vs 29.2%), whereas gastrointestinal adverse events were more frequent in black versus Hispanic participants (23.0% vs 1.4%). INTERPRETATION: Ocrelizumab treatment controlled disease activity in black and Hispanic people with relapsing multiple sclerosis. Results were consistent with pivotal ocrelizumab trials, supporting ocrelizumab's effectiveness and tolerability in these populations. ANN NEUROL 2026;100:793-807.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Amezcua L, Reder AT, Bernitsas E, et al. Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial. Ann Neurol. 2026. PMID: 42530333. doi:10.1002/ana.78290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。